Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
International Journal of Retina and Vitreous volume 8, Article number: 34 (2022)
Mineralocorticoid receptor antagonists (MRAs) are widely used for chronic central serous chorioretinopathy (cCSCR), but their effectiveness remains unclear. This research was conducted to evaluate the efficacy of this drugs for cCSCR.
This is a review of randomized clinical trials (RCT) comparing MRAs to placebo in adults with cCSCR, using the effects of MRAs on best-corrected visual acuity (BCVA) and adverse events as primary outcomes and the effects of MRAs on anatomical parameters as secondary outcomes: central subfield thickness (CST), subretinal fluid height (SFH) and central choroidal thickness (CCT). Our all-language online search included Medline (via PubMed), Central, Embase, Lilacs, Ibecs, and RCT registers platforms, as late as May 2021. We used the Cochrane risk-of-bias tool (version 2) to assess the methodological quality of each study and synthesized the results in meta-analyses using a random-effects model.
The search identified 302 records, five of which were eligible, totaling 225 cCSCR patients (aged 45–62 years; M/F ratio 3.1:1) treated for 1 to 12 months with spironolactone (50 mg/day) or eplerenone (50 mg/day) vs. placebo. Moderate-certainty evidence suggests MRAs result in little to no improvement in BCVA compared to placebo (SMD 0.22; 95% CI − 0.04 to 0.48; studies = 5; comparisons = 6; participants = 218; I2 = 0%). Very low-certainty evidence suggests that, when compared to placebo, MRAs have a very uncertain impact on adverse effects (no meta-analysis was performed), and CST (MD 18.1; 95% CI − 113.04 to 76.84; participants = 145; studies = 2; I2 = 68%). MRAs also result in little to no difference in SFH (SMD − 0.35; 95% CI − 0.95 to 0.26; studies = 5; comparisons = 6; participants = 221; I2 = 76%; moderate certainty) and CCT (MD − 21.23; 95% CI − 64.69 to 22.24; participants = 206; studies = 4; comparisons = 5; I2 = 85%; low certainty).
MRAs have little to no effect on BCVA. Evidence for adverse events and CST is very uncertain. MRAs also have little to no effect on SFH and CCT. These findings should be considered when prescribing MRAs for cCSCR.
This research was previous registration in the PROSPERO platform (CRD42020182601).
Central serous chorioretinopathy (CSCR) manifests as serous detachment of the neurosensory retina, occasionally associated with retinal pigment epithelial detachment (PED). CSCR is currently considered part of the pachychoroid spectrum, a group of diseases characterized by bulging of the large choroidal vessels and thinning of the choriocapillaris and Sattler’s layer .
CSCR is the fourth-most common non-surgical retinal disorder, after age-related macular degeneration, diabetic retinopathy and retinal vessel occlusion .The incidence of CSCR is 10/100,00 in men and 1.7/100,00 in women,  primarily affecting men 20–60 years of age .
CSCR is considered chronic (cCSCR) when subretinal fluid (SRF) persists for over 3–6 months .The period required for chronicity has not been established, but most authors adopt a 3-month cut-off to distinguish between acute and chronic cases [6,7,8]. Around 13% of cCSCR patients are legally blind ten years after disease onset. In this patient population, cystoid macular degeneration, choroidal neovascularization and outer retinal atrophy are associated with increased visual loss .
The proposed treatment for cCSCR targets the retinal pigment epithelium (RPE), the choroidal vessels, or both, in order to enhance the ability of the RPE to remove fluid, reduce choroidal leakage or reduce fluid flow through the external blood-retinal barrier [10, 11].
Despite the good level of safety and reasonable level of efficacy observed with the use of subthreshold micropulse laser treatment (SMPLT) for cCSCR in a number of reports [12,13,14,15,16,17], the rate of SRF resolution was lower in the PLACE trial  (the only randomized, prospective multicenter study of this type of treatment for cCSCR). Functional results are believed to be better when SMPLT is initiated early (before chronification) . On the other hand, half-fluence PDT has been shown to be more efficient than SMPLT at SRF resolution and functional recovery following treatment for cCSCR  and is currently the first treatment option, notwithstanding the prohibitive cost and limited availability.
Considering the involvement of high levels of endogenous or exogenous glucocorticoids in the genesis of CSCR and the activation of mineralocorticoid receptors by glucocorticoids, some authors believe this pathway is implicated in the development of CSCR [20, 21]. There is evidence of the presence of mineralocorticoid receptors in choroidal vessels, which, when activated, induce dilatation and increase vascular permeability, resulting in SRF accumulation. Thus, mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, became an alternative treatment for cCSCR [22,23,24,25,26,27,28,29]
Parallel [27, 28] or cross-over  controlled clinical trials have yielded conflicting results regarding the effect of MRAs on cCSCR. The effect on functional parameters, such as best-corrected visual acuity (BCVA), ranges from moderate [21, 29] to absent . A similar pattern is observed for anatomical parameters, with some studies showing improvements [23, 28, 29] and others showing no effect [27, 30].
The systematic reviews of randomized clinical trials (RCT) on the use of MRAs in cCSCR published so far have had serious limitations. A Cochrane review looking into the effects of several interventions for cCSCR  was published before the first RCTs on oral MRA therapy became available. Other relevant systematic reviews [32,33,34] pooled acute and chronic cases or pooled RCTs with other types of studies.
In the present review, we attempt to resolve the inconsistencies in the literature by employing the strictest possible methodological criteria in an evaluation of the efficacy and safety of MRAs in the treatment of cCSCR.
This systematic review with meta-analyses was conducted in compliance with Prisma 2020 recommendations  and was prospectively registered on PROSPERO platform (CRD42020182601).
Types of studies
We selected RCTs with parallel or cross-over design (analyzing the first stage only) which evaluated the administration of MRAs to cCSCR patients. The sample excluded non-randomized trials, trials pooling acute and chronic forms of CSCR, cohort studies, case–control studies, and case reports.
Types of participants/study population
To be eligible, participants had to be adult (≥ 18 years) and diagnosed with cCSCR on optical coherence tomography (OCT), fluorescein angiography, indocyanine green angiography, or a combination of these. Studies including patients with other macular conditions (e.g., choroidal neovascularization, macular degeneration and myopic maculopathy) were not eligible.
Types of interventions
RCTs evaluating the effects of MRAs (spironolactone and eplerenone) on cCSCR were eligible provided at least one control group (placebo or non-intervention) was included.
Types of outcome parameters
The primary outcome parameters were improvement in BCVA (assessed with a ETDRS chart or similar) and adverse events (including treatment-related vision loss, retinal atrophy and choroidal neovascularization). The secondary outcome parameters were central subfield thickness (CST), subretinal fluid height (SFH) and central choroidal thickness (CCT), estimated on Spectral Domain OCT. In each study we selected the data from the longest treatment period available.
The search universe included the databases Medline via PubMed (1996 to May 2021), Central (Issue 5, 2021), Embase (1974 to May 2021), Lilacs and Ibecs via VHL Regional Portal (1982 to May 2021) and three RCT platforms (https://clinicaltrials.gov, https://isrctn.com, https://ictrptest.azurewebsites.net), with no restrictions on publication language, date or status. Table 1 presents the search strategy. The search was complemented by screening the references of the selected studies and relevant systematic reviews.
The software Rayyan  allowed the team of reviewers to remove duplicates of the selected publications and manage the sample with transparency. The evaluation of eligibility was performed independently by two reviewers (VTC and NCJ). First, the studies were considered for inclusion based on their titles and abstracts. Selected publications were then submitted to full—text analysis. In case of disagreement, a third reviewer (CQ) was consulted and a consensus was reached. When necessary, the original authors were contacted for clarification.
Two reviewers (VTC and NCJ) independently retrieved the data and results of each publication, consulting a third reviewer (CQ) in the case of divergence. When further data were deemed necessary, the original authors were contacted.
The extracted data covered methodology (design, units of randomization and analysis), study population (country, number of subjects, age, sex, inclusion/exclusion criteria), interventions (number of subjects randomized for each group, drug name, dosage, frequency and route, and duration of treatment), and outcome parameters (see section above). Table 2 shows the main aspects of each study.
Assessment of risk of bias and certainty of evidence
Two reviewers (VTC and NCJ) independently assessed the risk of bias (using the Cochrane risk-of-bias tool version 2-RoB2) and the certainty of evidence in the selected studies, following the above procedure in the case of divergence.
The RoB2 covers the following dimensions: bias arising from the randomization process, bias due to deviations from the intended interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias in the selection of reported results. The study was focused on the ‘assignment to intervention’ (or ‘intention-to-treat’) effect at baseline. Within each domain, responses to signaling questions were either ‘yes’, ‘probably yes’, ‘no’, ‘probably no’ or ‘no information’. The final risk-of-bias judgment of the algorithm was ‘low risk of bias’, ‘some concerns’ or ‘high risk of bias’. The overall risk of bias of each result corresponded to that of the least favorable assessment in all domains.
We evaluated the certainty of evidence for each outcome with the software GRADEpro GDT. Certainty was downgraded by one level for serious limitations and by two levels for very serious limitations, based on predefined criteria (study limitations, inconsistency, indirectness, imprecision of estimates, and presence of publication bias). The final result fell into one of the following categories: high certainty, moderate certainty, low certainty, and very low certainty.
Measures of treatment effect and data synthesis
To conduct meta-analyses we employed the software Review Manager (RevMan 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2021), combining the effects in random effects models with the inverse-variance method or, when necessary, the generic inverse-variance method. We expressed the effects as mean difference (MD) and their respective 95% confidence intervals (95% CI) or standardized mean difference (SMD) and their respective intervals, grouping the studies according to the criteria of eligibility of each outcome. A minimal clinically important difference (MCID) was an improvement in BCVA of at least 5 letters on the ETDRS chart (or equivalent) or a 10% reduction in CST, SFH and CCT. We assessed the heterogeneity using Cochran`s Q and I2 tests and visual inspection of the forest plots. When the heterogeneity was important, accompanied by a statistical significance (P < 0.10), we investigated the possible reason through subgroup analysis according to treatment duration (< 3 months vs ≥ 3 months).
Sensitivity analysis and assessment of reporting bias
The sensitivity analysis used to assess the robustness of the data excluded studies with high risk of bias (or some concerns), unpublished studies and studies influenced by funding.
Finally, we planned to evaluate the influence of publication bias on the results using funnel plots and Egger’s test, provided each meta-analysis included at least 10 studies.
Availability of data and materials
The search yielded 233 records from the databases Medline (n = 124), Central (n = 20), Embase (n = 87) and Lilacs/Ibecs (via VHL Regional Portal) (n = 2), in addition to 69 records from specialized platforms. The elimination of duplicates left 269 records for title and abstract analysis, of which 261 were excluded, leaving 8 full articles for eligibility assessment. We subsequently excluded two studies because they included abstracts presented at events related to two studies already included and one study which was ongoing at the time of writing. The screening process left a final sample of 5 RCTs (all of which contained at least one meta-analysis) for qualitative and quantitative synthesis. Figure 1 shows the steps in the triage and inclusion of studies.
Studies included in the analysis
Table 2 shows the characteristics of the 5 studies included in the final sample: three two-armed, parallel-design RCTs, [27, 28, 30] one two-armed cross-over RCT,  and one three-armed RCT . One study was multicenter;  the remainder single-center [23, 27,28,29]. Treatment lasted 1 month, [23, 29] 2 months,  5 months,  or 12 months . Prepublished protocols were available for 4 studies.
Taken together, the 5 studies had 225 randomized participants, 221 of whom were analyzed regarding at least one of the outcome parameters. All studies included participants with cCSCR (‘chronic’ being defined as the presence of subretinal fluid for over 3 months). The mean age was 47–51 years for the groups treated with MRAs and 45–62 years for the control groups. The male/female ratio was 3.1:1.
Two studies [23, 29] compared spironolactone to placebo in pill form: 25 mg/day in the first week, 50 mg/day from the second week on (total: 1 month). Four studies [27,28,29,30] compared eplerenone to placebo in pill form: 25 mg/day in the first week, 50 mg/day from the second week on (total: 1–12 months). One study  (three-armed RCT) evaluated both drugs.
Risk of bias in the included studies
Three studies [23, 29, 30] completed the intended interventions with no deviations in any of the outcome parameters. Four studies performed adequate analyses based on intention to treat approach (or intention to treat with adjustments for missing data). One study  did not use an intention-to-treat approach and presented incomplete outcome data.
All studies presented the outcomes adequately, with the examiners blinded at all times (= low risk of bias).
Only one study  had an adequate plan of analysis for all outcomes (low risk of bias). No plan of analysis existed for most of the outcomes in the protocols of the other studies (= some concerns, or high risk of bias).
Only one study  had a low risk of bias overall for all outcomes. In one study,  the overall assessment was ‘some concerns’ for all outcomes, while another  displayed a high risk of bias for all outcomes in the overall risk assessment. One study  presented 'some concerns' for most outcomes, while another  presented high risk of bias for the outcomes 'macular thickness' and 'subfoveal choroidal thickness'. Figure 2 summarizes the risk of bias in each domain.
Since the number of RCTs included in the analysis was smaller than 10, we were unable to evaluate the influence of publication bias on the results (using funnel plots and Egger’s test), as originally intended.
Results of meta-analyses
The five included studies [23, 27,28,29,30] totaled 218 participants for this outcome. MRAs probably have little to no positive effect on BCVA (evaluated with the ETDRS chart or the Snellen chart and expressed in letter counting or logarithmic minimum angle of resolution) when compared to placebo. The effect ranged from ‘clinically unimportant improvement’ to ‘clinically unimportant worsening’ (SMD = 0.22; 95% CI − 0.04 to 0.48; studies = 5; comparisons = 6; I2 =0%) (Fig. 3).
On a scale from 0 to 100 letters (ETDRS chart; more letters = better BCVA), acuity improved by 0.99 letters in patients treated with MRAs (95% CI 0.18 fewer to 2.16 more letters; 1% absolute improvement [95% CI 0.2% worse to 2.2% better]; 1.27% relative improvement (95% CI 0.23% worse to 2.77% better; MCID = 5 letters). Applying the GRADE criteria, there is evidence of moderate certainty that MRAs have little (clinically unimportant) to no positive effect on BCVA when compared to placebo (evidence downgraded due to imprecision) (Table 3).
The five included studies [23, 27,28,29,30] totaled 225 participants for this outcome. When compared to placebo, the evidence for a positive effect of MRAs on adverse events is very uncertain. Applying the GRADE criteria, the evidence for this outcome is of very low certainty (evidence downgraded one level due to risk of bias and two levels due to imprecision) (Table 3).
Since the selected studies did not consistently report adverse events, no meta-analysis was performed for this outcome.
Central subfield thickness (CST)
The three studies [27, 28, 30] evaluating CST totaled 143 participants. The evidence of MRA-induced reduction in CST on OCT (smaller = better) when compared to placebo is very uncertain, ranging from clinically important improvement to clinically important worsening (MD -18.1 [95% CI − 113.04 to 76.84]; studies = 3; I2 = 68%; absolute percentage difference not applicable [data not expressed on a scale]; relative percentage improvement = 4.9% [95% CI 20.8 worse to 30.6 better]; MCID = 10%) (Fig. 4). Applying the GRADE criteria, the evidence for CST reduction was of very low certainty, compared to placebo (evidence downgraded one level due to risk of bias and two levels due to imprecision) (Table 3).
We also analyzed a subgroup of participants treated with MRA for less than 3 months (short-term effect). When compared to controls, the MRA group displayed a 117.5 μm reduction in CST (95% CI 224.45 smaller to 10.55 smaller; participants = 15; studies = 1; I2 = not applicable; absolute percentage difference not applicable; relative percentage improvement = 34.1% [95% CI 3.1% better to 65.1% better]; MCID = 10%). Applying the GRADE criteria, the evidence for MRA-induced CST reduction in up to 3 months of treatment is very uncertain when compared to placebo (evidence downgraded one level due to risk of bias and two levels due to imprecision). In the subgroup of participants treated for more than 3 months (long-term effects), CST increased by 24.56 μm (95% CI − 6.96 smaller to 56.08 bigger; participants = 130; studies = 2; I2 = 0%; absolute percentage difference not applicable; relative percentage worsening = 7.4% [95% CI 16.9% worse to 2.1% better]; MCID = 10%). Applying the GRADE criteria, the evidence that over 3 months of treatment with MRA results in little to no reduction in CST when compared to placebo is uncertain (evidence downgraded two levels due to imprecision).
With the exclusion of one study,  the sensitivity analysis modified the estimated effect of MRAs from a slight reduction to a slight increase in CST, when compared to placebo (MD 24.56 [95% CI − 6.96 to 76.84]; participants = 130; studies = 2; I2 = 0%).
Subretinal fluid height (SFH)
Five studies [23, 27,28,29,30] totaling 221 participants evaluated this outcome. One study compared spironolactone to placebo, three studies compared eplerenone to placebo, and one study tested both drugs in relation to placebo. When compared to placebo, MRAs probably have little to no effect on SFH reduction on OCT (smaller = better), ranging from clinically unimportant improvement to clinically unimportant worsening (SMD -0.35 [95% CI − 0.95 to 0.26]; studies = 5; comparisons = 6; I2 = 76%) (Fig. 5).
On OCT (smaller = better), the SFH of participants treated with MRA decreased by 2.17 μm (95% CI − 5.89 less to 1.61 more; absolute percentage difference not applicable [data not expressed on a scale]; relative percentage improvement = 1.82% [95% CI 1.35% worse to 4.95% better]; MCID = 10%). Applying the GRADE criteria, the evidence that MRAs have little to no effect on SFH is moderately certain, when compared to placebo (evidence downgraded one level due to imprecision) (Table 3).
We also analyzed a subgroup of participants treated with MRA for less than 3 months (short-term effect). When compared to controls, the MRA group displayed a 57.72 μm reduction in SFH (95% CI 92.35 smaller to 23.1 smaller; participants = 90; studies = 3; comparisons = 4; I2 = 0%; absolute percentage difference not applicable; relative percentage improvement = 42.5% [95% CI 17% better to 68% better]; MCID = 10%). Applying the GRADE criteria, we found moderately certain evidence that treatment with MRAs for up to three months probably reduces SFH, when compared to placebo (evidence downgraded one level due to imprecision). The subgroup of participants treated for over 3 months (long-term effect) displayed a 2.9 μm increase in SFH (95% CI 0.74 greater to 5.1 greater; participants = 133; studies = 2; I2 = 0%; absolute percentage difference not applicable; relative percentage worsening = 0.02% [95% CI 0.01% worse to 0.04% worse]; MCID = 10%). Applying the GRADE criteria, the evidence that treatment with MRA for over 3 months produces little to no increase in SFH, when compared to placebo, is moderately certain (evidence downgraded one level due to imprecision).
With the exclusion of one study,  the sensitivity analysis confirmed that MRAs probably cause little to no change in SFH, in relation to placebo (MD − 1.2 [95% CI − 4.8 to 2.5]; participants = 228; studies = 4; comparisons = 3; I2 = 74%).
Central choroidal thickness (CCT)
Four studies [23, 27, 29, 30] totaling 206 participants evaluated this outcome. One study compared spironolactone to placebo, two studies compared eplerenone to placebo, and one study evaluated both drugs in relation to placebo. When compared to placebo, MRAs may have little to no effect on CCT reduction on OCT (smaller = better), ranging from clinically important improvement to clinically unimportant worsening (MD − 21.23 [95% CI − 64.69 to 22.24; studies = 4; comparisons = 5; I2 = 85%; absolute percentage difference not applicable [data not expressed on a scale]; relative percentage of improvement = 4.6% [95% CI 4.8% worse to 14% better]; MCID = 10%) (Fig. 6). Applying the GRADE criteria, the evidence that MRAs result in little to no difference in CCT is of low certainty, when compared to placebo (evidence downgraded one level due to risk of bias and one level due to imprecision) (Table 3).
We also analyzed a subgroup of participants treated with MRA for less than 3 months (short-term effect). When compared to controls, the MRA group displayed a 46.48 μm reduction in CCT (95% CI 65.59 smaller to 27.38 smaller; participants = 75; studies = 2; comparisons = 3; I2 = 0%; absolute percentage difference not applicable; relative percentage of improvement = 10% [95% CI 5.9% better to 14% better]; MCID = 10%). Applying the GRADE criteria, the evidence that up to 3 months of treatment with MRAs reduces CCT slightly in comparison to placebo was moderately certain (evidence downgraded one level due to imprecision). The subgroup of participants treated for over three months (long-term effect) displayed a 37.69 μm increase in CCT (95% CI 12.01 greater to 63.37 greater; participants = 133; studies = 2; I2 = 0%; absolute percentage difference not applicable; relative percentage of worsening = 8.2% [95% CI 2.6% worse to 13.8% worse]; MCID = 10%). Applying the GRADE criteria, the evidence that over 3 months of treatment with MRAs results in increased CCT when compared to placebo is moderately certain (evidence downgraded one level due to imprecision).
With the exclusion of one study,  the sensitivity analysis modified the estimated effect of MRAs, from little or no reduction in CT to little or no increase in CCT, when compared to placebo (MD 1.94 [95% CI − 65.54 to 69.41]; participants = 148; studies = 3; I2 = 87%).
To our knowledge, this is the first systematic review with meta-analyses focusing exclusively on RCTs evaluating clinical response to MRA in the treatment of cCSCR.
The included studies show that eplerenone and spironolactone affect BCVA in cCSCR patients ranging from clinically unimportant worsening to clinically unimportant improvement (moderate certainty; downgrading due to imprecision). The effect of MRAs on CST is very uncertain (downgrading due to risk of bias, inconsistency and imprecision). Likewise, MRAs result in little to no change in SFH (moderate certainty; downgrading due to imprecision) or CCT (low certainty; downgrading due to risk of bias and imprecision).
All the RCTs included in this review investigated the effect of MRAs vs placebo in treatments lasting 1–12 months, using dosages of 25–50 mg/day. In clinical practice the minimum duration of treatment with these drugs has not been established, but the fact that most physicians prescribe them for three or more months at a dosage of 25–50 mg/day suggests the reviewed RCTs are representative of actual clinical practice. The male/female proportion in the five RCTs (3.1:1) was lower than in most other studies, [3, 4] but the age range (47–51 years) was compatible with the literature [3, 4].
Although the reviewed RCTs were considered to have low risk of bias in most domains, the meta-analyses for CST, SFH and CCT displayed high levels of heterogeneity, possibly due to the wide variation in treatment duration (1–12 months). In fact, anatomical outcomes were generally better in studies with shorter periods of treatment (1–2 months) [23, 28, 29].
A Cochrane systematic review with meta-analyses  published in 2010 investigated the efficacy of available treatments for cCSCR but did not include comparisons between MRAs and placebo, as in the present study. The earliest studies making such comparisons [22,23,24] were published after 2010.
The most recent systematic reviews with meta-analyses [32,33,34] pooled acute and chronic cases of CSCR. However, the inclusion of acute cases may confound the analysis of the efficacy of MRAs due to the high likelihood of anatomical and functional recovery of patients with the acute form, even without interventions [37,38,39]. We therefore only reviewed RCTs focused on the chronic form. Another systematic review with meta-analysis  from 2018 was conducted before the publication of the Vici Trial , which currently has the lowest risk of methodological bias of any RCT on the subject, thus with a possible potential impact on the statistical analysis. Finally, a Chinese systematic review with meta-analysis  included both RCTs and observational studies, without segregating them in the results. This fact may have contributed to the appearance of a positive effect of MRAs on anatomical parameters (SFH and CCT).
Improvement in BCVA in CSCR patients requires the recovery of the macular architecture and photoreceptor function, once the SRF has been absorbed . Some recent studies have shown the existence of functional damage in the first months after SRF accumulation, with potential negative impacts on the patients quality of life,  raising the issue of the benefit of early onset of therapy [4, 41, 42] for patients with CSCR. The absence of clinically important improvement in BCVA in the current review may be explained by the fact that chronic CSCR patients treated with MRAs experience little to no reduction in SFH.
In this review we conducted a comprehensive search in major databases and RCT platforms, identifying both published and unpublished studies, thereby minimizing the risk of publication bias. On the other hand, the small number of RCTs included in the quantitative synthesis (n = 5) made it impossible to statistically verify the presence of publication bias.
One of the challenges encountered in this review was the high level of heterogeneity in three of the meta-analyses. We did not evaluate heterogeneity by analyzing preplanned subgroups (age, sex, type of personality, corticoid use, gastric infection with Helicobacter pylori, smoking, sleep and circadian rhythm disorders, exogenous use of testosterone, occupational activity) due to the absence of specific results, but when the participants were segregated according to time of treatment, the inconsistency was explained.
Reliance on only 5 RCTs with a small number of participants and without sample size calculation (with one exception)  may have influenced the estimates of our meta-analyses. Moreover, the non-standardized cross-over design of two of the studies [23, 29] (one of which was three-armed) may have biased the summary estimate due to carry-over effects.
In view of the multifactorial nature of CSCR  and the prohibitive cost of state-of-the-art therapies like PDT, [6,7,8, 37] treating patients with the chronic form can be challenging. Over the last few years, MRAs have emerged as a safe and accessible alternative, although the efficacy of these drugs remains uncertain [22, 24,25,26,27,28,29,30, 32].
This review found that MRAs (spironolactone and eplerenone) have little to no effect on functional and anatomical outcomes in cCSCR patients. The evidence presented is relevant to current management of the condition, but further studies on larger samples and longer treatment periods (> 3 months) are needed to obtain a better estimate of the effect of interventions.
Availability of data and materials
Central serous chorioretinopathy
Pigment epithelial detachment
Chronic Central serous chorioretinopathy
Retinal pigment epithelium
Mineralocorticoid receptor antagonists
Best-corrected visual acuity
Randomized clinical trials
Early Treatment Diabetic Retinopathy Study
Central subfield thickness
Subretinal fluid height
Central choroidal thickness
Optical coherence tomography
- 95% CI:
95% confidence intervals
Standardized mean difference
Minimal clinically important difference
Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye. 2019;33(1):14–33. https://doi.org/10.1038/s41433-018-0158-4.
Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126–45. https://doi.org/10.1111/j.1600-0420.2007.00889.x.
Kitzmann AS, Pulido JS, Diehl NN, et al. The Incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73. https://doi.org/10.1016/j.ophtha.2007.02.032.
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73: 100770. https://doi.org/10.1016/j.preteyeres.2019.07.003.
Wong KH, Lau KP, Chhablani J, et al. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol. 2016;94(4):321–5. https://doi.org/10.1111/aos.12779.
Chan WM, Lai TYY, Lai RYK, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93. https://doi.org/10.1097/IAE.0b013e318156777f.
Reibaldi M, Cardascia N, Longo A, et al. Standard-Fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307–15. https://doi.org/10.1016/j.ajo.2009.08.026.
Shin JY, Woo SJ, Yu HG, et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011;31(1):119–26. https://doi.org/10.1097/IAE.0b013e3181e378f2.
Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-term Visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. 2019;126(4):576–88. https://doi.org/10.1016/j.ophtha.2018.12.048.
Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26. https://doi.org/10.1016/J.SURVOPHTHAL.2012.07.004.
Quin G, Liew G, Van HI, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41(2):187–200. https://doi.org/10.1111/j.1442-9071.2012.02847.x.
Luttrull JK. Low-intensity/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina. 2016;36:1658–63. https://doi.org/10.1097/IAE.0000000000001005.
Yadav NK, Jayadev C, Mohan A, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye. 2015;29:258–64. https://doi.org/10.1038/eye.2014.315.
Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253:2129–35. https://doi.org/10.1007/s00417-015-2965-7.
Malik KJ, Sampat KM, Mansouri A, et al. Low-intensity/highdensity subthreshold micropulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35:532–6. https://doi.org/10.1097/IAE.0000000000000285.
Roca JA, Wu L, Fromow-Guerra J, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018. https://doi.org/10.1136/bjophthalmol-2017-311291.
Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye. 2018;32:726–33. https://doi.org/10.1038/eye.2017.293.
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The place trial. Ophthalmology. 2018;125(10):1547–55. https://doi.org/10.1016/j.ophtha.2018.04.021.
Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset. J Clin Med. 2019;8(9):1398. https://doi.org/10.3390/jcm8091398.
Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672–9. https://doi.org/10.1172/JCI61427DS1.
van Dijk EHC, Nijhoff MF, de Jong EK, et al. Central serous chorioretinopathy in primary hyperaldosteronism. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(10):2033–42. https://doi.org/10.1007/s00417-016-3417-8.
Bousquet E, Zhao M, Daruich A, et al. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: review of the pre-clinical and clinical evidence. Exp Eye Res. 2019;187: 107754. https://doi.org/10.1016/j.exer.2019.107754.
Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35(12):2505–15.
Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33(10):2096–102. https://doi.org/10.1097/IAE.0b013e318297a07a.
Gergely R, Kovács I, Schneider M, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37(6):1084–91. https://doi.org/10.1097/iae.0000000000001303.
Rajesh B, Agrawal H, Peguda HK, et al. Predictors of outcome during eplerenone therapy in chronic central serous chorioretinopathy: a prospective, open-label pilot clinical study. Ophthalmic Surg Lasers Imaging Retina. 2018;49(7):479–86. https://doi.org/10.3928/23258160-20180628-03.
Schwartz R, Habot-Wilner Z, Martinez MR, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95(7):e610–8. https://doi.org/10.1111/aos.13491.
Rahimy E, Pitcher JD, Hsu J, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina. 2018;38(5):962–9. https://doi.org/10.1097/IAE.0000000000001649.
Pichi F, Carrai P, Ciardella A, et al. Comparison of two mineralocorticosteroid receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017;37(5):1115–25. https://doi.org/10.1007/s10792-016-0377-2.
Lotery A, Sivaprasad S, O’Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):294–303. https://doi.org/10.1016/S0140-6736(19)32981-2.
Salehi M, Wenick AS, Law HA, et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;2015(12):CD011841. https://doi.org/10.1002/14651858.CD011841.pub2.
Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye. 2021;35(4):1102–10. https://doi.org/10.1038/s41433-020-01338-4.
Zhang B, Chou Y, Zhao X, et al. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis. Int Ophthalmol. 2020;40(11):2957–67. https://doi.org/10.1007/s10792-020-01479-1.
Wang SK, Sun P, Tandias RM, et al. mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials. Ophthalmol Retin. 2019;3(2):154–60. https://doi.org/10.1016/j.oret.2018.09.003.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10. https://doi.org/10.1186/s13643-016-0384-4.
Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3. https://doi.org/10.1016/j.ajo.2009.11.017.
Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24(12):1743–56. https://doi.org/10.1038/eye.2010.130.
Daruich A, Matet A, Marchionno L, et al. Acute central serous chorioretinopathy. Retina. 2017;37(10):1905–15. https://doi.org/10.1097/IAE.0000000000001443.
Breukink MB, Dingemans AJ, den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2016;11:39–46. https://doi.org/10.2147/OPTH.S115685.
Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019;19(1):160. https://doi.org/10.1186/s12886-019-1171-5.
Gawęcki M, Jaszczuk A, Grzybowski A. Short term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function. J Clin Med. 2020;9(11):3429. https://doi.org/10.3390/jcm9113429.
Bousquet E, Dhundass M, Lehmann M, et al. Shift Work: a risk factor for central serous chorioretinopathy. Am J Ophthalmol. 2016;165:23–8. https://doi.org/10.1016/j.ajo.2016.02.012.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Felipe, C.Q., Biancardi, A.L., Civile, V.T. et al. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retin Vitr 8, 34 (2022). https://doi.org/10.1186/s40942-022-00385-1
- Central Serous Chorioretinopathy
- Mineralocorticoid Receptor Antagonists